KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abbott Laboratories (ABT) Other Operating Expenses (2016 - 2025)

Abbott Laboratories' Other Operating Expenses history spans 17 years, with the latest figure at $5.3 billion for Q4 2025.

  • For Q4 2025, Other Operating Expenses fell 1.17% year-over-year to $5.3 billion; the TTM value through Dec 2025 reached $21.0 billion, up 2.03%, while the annual FY2025 figure was $21.0 billion, 2.03% up from the prior year.
  • Other Operating Expenses for Q4 2025 was $5.3 billion at Abbott Laboratories, down from $5.5 billion in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $5.5 billion in Q1 2022 and bottomed at $4.8 billion in Q1 2023.
  • The 5-year median for Other Operating Expenses is $5.1 billion (2022), against an average of $5.2 billion.
  • The largest annual shift saw Other Operating Expenses soared 42.85% in 2021 before it decreased 12.31% in 2023.
  • A 5-year view of Other Operating Expenses shows it stood at $5.3 billion in 2021, then dropped by 3.62% to $5.1 billion in 2022, then decreased by 1.02% to $5.0 billion in 2023, then increased by 7.35% to $5.4 billion in 2024, then decreased by 1.17% to $5.3 billion in 2025.
  • Per Business Quant, the three most recent readings for ABT's Other Operating Expenses are $5.3 billion (Q4 2025), $5.5 billion (Q3 2025), and $5.3 billion (Q2 2025).